Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06229769

Natural History Study for Patients With Angelman Syndrome

This study is a 9-year natural history study for patients with Angelman syndrome in Belgium (a genetic neurodevelopmental disorder, affecting 500,000 individuals in the world). It includes a 3-year recruitment phase, a 5 year follow-up and a year to analyze the collected data. The investigators plan to include 30 patients with a semi-annual follow-up for 4 years.

The investigators will collect relevant retrospective and prospective data using age-standardized scales and questionnaires for functional motor assessments and global developmental assessment.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

CHR Citadelle Liège

Liège, 4000, Belgium

Location status: Recruiting

Location contact

Laura Vanden Brande, Dr.

PRINCIPAL_INVESTIGATOR

Noor Benmhammed

CONTACT

[email protected]

43217726 ext. +32

Tamara Dangouloff, PhD

CONTACT

[email protected]

43215269 ext. +32

About this study

Patients are seen every six months for five years. In these visits, patient have medical review (general medical examination, neurological examination), vital signs (height, weight, respiratory rate, heart rate, blood pressure), cognitive assessment (Bayley-IV), language assessment and questionaire (Bayley-IV, ORCA), motor assessments (Bayley-IV, FMS, Developmental milestones and HINE), quality of life questionnaire (PedsQL, CGI-CASS) and general development questionnaire (Vineland-II).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Genetically confirmed diagnosis of AS
  • 0-99 years
  • Male or Female
  • Participant's carer is willing to give IC/sign a "record of consultation" for participation in the study

Exclusion criteria

  • comorbidity that could potentially affect the results of the study coexists. This

Treatment and study plan

Primary outcomes

  1. Bayley-IV gross motor functions

    Time frame: 2 years

    Scale of 58 items of Gross motor (raw score 0 to 116) development evaluation.

  2. Bayley-IV fine motor functions

    Time frame: 2 years

    Scale of 46 items of fine motor scale (raw score 0 to 92) development evaluation.

  3. Bayley-IV Cognitive

    Time frame: 2 years

    Scale of 81 items of cognitive scale development evaluation (raw score 0 to 162).

  4. Bayley-IV Receptive Communication

    Time frame: 2 years

    Scale of 42 items of receptive communication abilities scale in development evaluation (raw score 0 to 84).

  5. Bayley-IV Expressive Communication

    Time frame: 2 years

    Scale of 37 items of expressive communication abilities scale in development evaluation (raw score 0 to 74).

  6. Functional Mobility Scale (FMS)

    Time frame: 2 years

    Scale o 3 items (5, 50 and 500 meters distance of ability to move alone) to classify children's functional mobility, document change over time in the same child and to document change seen following. This scale is scored 1 (moving alone with wheelchair) to 6 (running).

  7. Developmental Milestones

    Time frame: 2 years

    Scale to Evaluate the general gross motor milestones of 6 items global motor ability, from ability to sit without support to walk alone (score by able or not able). .

  8. Hammersmith Infant Neurological Examination (HINE - if under 2 years old)

    Time frame: 2 years

    Scale of 8 items to evaluation the mobility in young children, scored 0 (unable) to 4 (able and normal for children age) per items (total raw score from 0 to 32).

  9. Vineland-II

    Time frame: 2 years

    11 subscales of items evaluated with Caregivers interview tool for assessing the level of autonomy and adaptation for all ages.

    Subscales are composed as following (higher scores with better the abilites):

    • Listening and understanding, raw score 0 to 40;
    • Speaking, raw score 0 to 108,
    • Reading and writing, raw score 0 to 54,
    • Self caring, raw score 0 to 82,
    • Home caring, raw score 0 to 48,
    • Community living, raw score 0 to 88,
    • Contact with others, raw score 0 to 76,
    • Play and use your free time, raw score 0 to 62,
    • Adapting, raw score 0 to 60,
    • Gros motor, raw score 0 to 80,
    • Fine motor, raw score 0 to 72,
  10. Observed Reported Communication Assessment (ORCA)

    Time frame: 2 years

    Caregivers interview of 23 items with subscales to assessing the general communication.

    This is a qualitative questionnaire.

  11. Continuous movement monitoring using ActiMyo®

    Time frame: 2 years

    To improve the design of future clinical trials by validating tools of assessment based on their suitability to be used as prognostic measures.

Secondary outcomes

  1. Clinical Global Impression - Improvement - Angelman Syndrome (CGI-I-AS)

    Time frame: 2 years

    Caregivers interview of quality of life severity and change in patient with Angelman Syndrome since last 7 days and since the last month.

    Part regarding the severity in last 7 days is composed of 9 items scored 0 ("not at all difficult") to 4 ("very difficult"), raw score is between 0 to 36.

    Part regarding change in last month is composed of 9 items scored 1 ("very much improved") to 7 ("very much worse"), raw score is between 0 to 63,

  2. Pediatric Quality of Life (PedsQL)

    Time frame: 2 years

    Caregivers interview of quality of life and family impact in daily life separated in two parts, one regarding the last 7 days and one regarding the last month.

    Total raw score for each part is on 100 (100 related to no impact to 0 related to a huge impact).

Other outcomes

  1. Blood sample collection and DNA extraction and storage

    Time frame: 1 year

    To create a DNA biobank

Study contacts

Contact information is provided by the study sponsor or research team.

Noor Benmhammed

CONTACT

[email protected]

43217726 ext. +32

Tamara Dangouloff, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Liege

Other

Collaborators

  • Centre Hospitalier Régional de la Citadelle
  • SYSNAV

Registry information

Official study title

A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in CHR Citadelle Liège : NatHis-Angelman

Acronym: NatHisAngelman

Important dates

Study start
2021
Primary completion
2028
Study completion
2028
First posted
Jan 29, 2024
Registry last updated
May 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.